Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0031 USD
Change Today -0.0009 / -22.50%
Volume 170.0K
As of 12:16 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

accentia biopharmaceuticals (ABPI) Snapshot

Open
$0.0039
Previous Close
$0.0040
Day High
$0.0039
Day Low
$0.0031
52 Week High
10/14/14 - $0.03
52 Week Low
09/3/14 - $0.0012
Market Cap
278.2K
Average Volume 10 Days
88.2K
EPS TTM
$-0.25
Shares Outstanding
89.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACCENTIA BIOPHARMACEUTICALS (ABPI)

Related News

No related news articles were found.

accentia biopharmaceuticals (ABPI) Related Businessweek News

No Related Businessweek News Found

accentia biopharmaceuticals (ABPI) Details

Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily discovers, develops, and commercializes immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and development quantities of cell culture products from mammalian cell lines; Multi-6 for producing six monoclonal antibodies; AutovaxID, an automated cell culture system for production of personalized cell-based treatments and various additional vaccines; Acusyst-miniMax system, which offers two single-use disposables options to meet various production requirements; Acusyst-Maximizer, a system for process development and routine productions; and Acusyst-Xcellerator, a production-scale cell culture system. In addition, the company manufactures mammalian cell culture products, such as whole cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, media evaluation, and other related services. Further, it sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. The company provides its cell culture products and services to biopharmaceutical and biotechnology companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. Accentia Biopharmaceuticals, Inc. was founded in 2002 and is headquartered in Tampa, Florida.

51 Employees
Last Reported Date: 12/26/12
Founded in 2002

accentia biopharmaceuticals (ABPI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABPI:US $0.00 USD -0.0009

ABPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABPI.
View Industry Companies
 

Industry Analysis

ABPI

Industry Average

Valuation ABPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCENTIA BIOPHARMACEUTICALS, please visit www.accentia.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.